Subtype
Ovarian Neoplasm
CI-CAN-00001335Explore in graph →
Non-malignant746 active trials5 approved drugs94 evidence items
Loading cancer entity…
Subtype
CI-CAN-00001335Explore in graph →
Clinical trials
3,430 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03349463 | Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers. | unknown | Phase 4 | 30 | Bital Savir-BaruchOTHER | 1 | Feb 28, 2020 | clinicaltrials |
| NCT03150121 | Biomarkers for Early Detection of Ovarian Cancer Using Uterine Lavage(BEDOCA) | unknown | N/A | 500 | Sheba Medical CenterOTHER_GOV | 1 | Feb 26, 2020 | clinicaltrials |
| NCT04261465 | NUVOLA TRIAL Open-label Multicentre Study(NUVOLA) | unknown | Phase 2 | 35 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Feb 7, 2020 | clinicaltrials |
| NCT04224467 | The Application of Real-Time Near-infrared Imaging in Gynecological Surgery | unknown | N/A | 500 | Chen ChunlinOTHER | 1 | Jan 14, 2020 | clinicaltrials |
| NCT00499512 | Role of Spirituality in Coping and Surviving With Ovarian Cancer, Primary Peritoneal or Fallopian Tube Cancer | unknown | — | 115 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 10, 2020 | clinicaltrials |
| NCT04191252 | Genetic Mutation in Epithelial Ovarian Cancer | unknown | — | 500 | Lei LiOTHER | 1 | Dec 20, 2019 | clinicaltrials |
| NCT04066335 | Study to Evaluate the Safety of Nanoxel M Inj. | unknown | — | 1,498 | Samyang Biopharmaceuticals CorporationINDUSTRY | 1 | Dec 18, 2019 | clinicaltrials |
| NCT03638206 | Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | unknown | Phase 1 / Phase 2 | 73 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Dec 11, 2019 | clinicaltrials |
| NCT03693248 | Reduction Of Cycles of neOadjuvant Chemotherapy for Advanced Epithelial Ovarian, Fallopian and Primary Peritoneal Cancer(ROCOCO) | unknown | Phase 3 | 298 | Seoul National University HospitalOTHER | 1 | Dec 10, 2019 | clinicaltrials |
| NCT04190667 | Homologous Recombination Deficiency Status in Epithelial Ovarian Cancer | unknown | — | 1,300 | Lei LiOTHER | 1 | Dec 10, 2019 | clinicaltrials |
| NCT04176484 | Feasibility of Opportunistic Salpingectomy During Non-Gynecologic Surgery | unknown | — | 150 | University of VirginiaOTHER | 0 | Nov 29, 2019 | clinicaltrials |
| NCT03373058 | Efficacy of HIPEC in the Treatment of Advanced-Stage Epithelial Ovarian Cancer After Cytoreductive Surgery(EHTASEOCCS) | unknown | Phase 3 | 310 | Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityOTHER | 1 | Nov 6, 2019 | clinicaltrials |
| NCT03220932 | Cytoreductive Surgery and HIPEC in First or Secondary Platinum-resistant Recurrent Ovarian Epithelial Cancer(HIPOVA-01) | unknown | Phase 3 | 132 | Hospices Civils de LyonOTHER | 1 | Nov 1, 2019 | clinicaltrials |
| NCT03210298 | International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)(PIPACRegis) | unknown | — | 1,000 | Sabine RhodeOTHER | 13 | Oct 8, 2019 | clinicaltrials |
| NCT04000295 | Apatinib and Etoposide Capsule Versus Weekly Paclitaxel in Patients With Platinum Resistant Ovarian Cancer | unknown | Phase 3 | 280 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Oct 8, 2019 | clinicaltrials |
| NCT04101760 | Granulocyte Colony Stimulating Factor for for the Prevention of Febrile Neutropenia in Epithelial Ovarian Cancer | unknown | Phase 3 | 200 | Lei LiOTHER | 1 | Oct 8, 2019 | clinicaltrials |
| NCT03302884 | Circulating Tumor DNA as an Early Marker of Recurrence and Treatment Efficacy in Ovarian Carcinoma(CIDOC) | unknown | N/A | 150 | Institut Paoli-CalmettesOTHER | 1 | Sep 26, 2019 | clinicaltrials |
| NCT03556566 | Open Label Immunotherapy Trial for Ovarian Cancer(V3-OVA) | unknown | Phase 2 | 20 | Immunitor LLCINDUSTRY | 1 | Aug 30, 2019 | clinicaltrials |
| NCT04055038 | Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC)(EPITOC) | unknown | Phase 2 / Phase 3 | 164 | Blokhin's Russian Cancer Research CenterOTHER | 1 | Aug 13, 2019 | clinicaltrials |
| NCT04001023 | Overcoming Chemoresistance in Advanced Ovarian Cancer Via Targeting Hypoxia(OVANOX) | unknown | N/A | 40 | Turku University HospitalOTHER_GOV | 1 | Aug 7, 2019 | clinicaltrials |
| NCT04029909 | A Clinical Study of Gimatecan in Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer | unknown | Phase 1 | 12 | Lee's Pharmaceutical LimitedINDUSTRY | 1 | Jul 23, 2019 | clinicaltrials |
| NCT01267851 | Clinical Database and Biobank of Patients With Gynecologic Neoplasms | unknown | — | 1,600,000 | Huazhong University of Science and TechnologyOTHER | 1 | Jul 19, 2019 | clinicaltrials |
| NCT04022863 | Ovarium Cancer Detection by TEP's and ctDNA | unknown | — | 500 | Gynaecologisch Oncologisch Centrum ZuidOTHER | 1 | Jul 17, 2019 | clinicaltrials |
| NCT03448354 | Comparative Effectiveness of HIPEC Following Interval Debulking Surgery in Patients With Advanced-stage Ovarian Cancer | unknown | N/A | 204 | Ajou University School of MedicineOTHER | 1 | Jul 5, 2019 | clinicaltrials |
| NCT00511641 | Quality of Life Associated With a Low-Risk Screening Program for Ovarian Cancer | unknown | — | 1,342 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 24, 2019 | clinicaltrials |
| NCT03942068 | Apatinib With Albumin-bound Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer | unknown | Phase 2 | 35 | Henan Cancer HospitalOTHER_GOV | 0 | May 8, 2019 | clinicaltrials |
| NCT03924882 | Anlotinib for Patients With Platinum Resistant or Refractory Ovarian Cancer | unknown | Phase 2 | 30 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 23, 2019 | clinicaltrials |
| NCT02349958 | Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy(HIPEC/IPHC) | unknown | Phase 2 | 200 | Bay Area Gynecology OncologyOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT03916679 | MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer | unknown | Phase 1 / Phase 2 | 20 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT03799913 | MESO-CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer | unknown | Early Phase 1 | 20 | Zhejiang UniversityOTHER | 1 | Apr 10, 2019 | clinicaltrials |
| NCT03412526 | Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Ovarian | unknown | Phase 2 | 15 | Sheba Medical CenterOTHER_GOV | 1 | Apr 4, 2019 | clinicaltrials |
| NCT03846856 | The IGF Axis Involvement in Immune Tumor Microenvironment in Ovarian Cancer and Its Clinical Significance | unknown | — | 40 | Hillel Yaffe Medical CenterOTHER_GOV | 1 | Apr 4, 2019 | clinicaltrials |
| NCT03895788 | A Study of Niraparib in Combination With Brivanib in Recurrent Ovarian Cancer | unknown | Phase 1 | 24 | Hunan Cancer HospitalOTHER | 1 | Mar 29, 2019 | clinicaltrials |
| NCT03150992 | EDMONd - Elemental Diet in Bowel Obstruction(EDMONd) | unknown | N/A | 34 | Royal Surrey County Hospital NHS Foundation TrustOTHER | 1 | Mar 26, 2019 | clinicaltrials |
| NCT00958698 | Symptom Management in Patients With Recurrent or Persistent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | unknown | N/A | 485 | Gynecologic Oncology GroupNETWORK | 1 | Mar 12, 2019 | clinicaltrials |
| NCT01372787 | Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer | unknown | — | 103 | Gynecologic Oncology GroupNETWORK | 1 | Mar 12, 2019 | clinicaltrials |
| NCT03112733 | Serum Biomarkers in Diagnosis and Predicting Prognosis of Ovarian Cancers | unknown | — | 171 | Ilker KahramanogluOTHER | 1 | Feb 26, 2019 | clinicaltrials |
| NCT03818282 | Efficacy and Safety of Paclitaxel for Injection (Albumin-bound) for First-line Chemotherapy of Ovarian Cancer(OC-01) | unknown | Phase 2 | 77 | Huazhong University of Science and TechnologyOTHER | 0 | Feb 26, 2019 | clinicaltrials |
| NCT02433626 | Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies(COTI2-101) | unknown | Phase 1 | 51 | Critical Outcome Technologies Inc.INDUSTRY | 1 | Feb 1, 2019 | clinicaltrials |
| NCT03692637 | Study of Anti-Mesothelin Car NK Cells in Epithelial Ovarian Cancer | unknown | Early Phase 1 | 30 | Allife Medical Science and Technology Co., Ltd.INDUSTRY | 0 | Jan 31, 2019 | clinicaltrials |
| NCT03808792 | Imaging Study in Advanced Ovarian Cancer(ISAAC) | unknown | — | 400 | Charles University, Czech RepublicOTHER | 1 | Jan 18, 2019 | clinicaltrials |
| NCT02950064 | A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations | unknown | Phase 1 | 95 | Placon TherapeuticsINDUSTRY | 1 | Jan 14, 2019 | clinicaltrials |
| NCT03634501 | Clinical Study on Anti-tumor Effect Induced by Activated Primary Natural Killer(NK)Cells | unknown | Phase 1 / Phase 2 | 200 | Xuanwu Hospital, BeijingOTHER | 1 | Jan 11, 2019 | clinicaltrials |
| NCT03763123 | A Phase 1b Study of Sevacizumab in Combination With Chemotherapy in Chinese Patients With Platinum-Resistant Recurrent Ovarian Cancer. | unknown | Phase 1 | 48 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 4, 2018 | clinicaltrials |
| NCT03517332 | Circulating Tumor DNA Exposure in Peripheral Blood | unknown | — | 10,000 | Quantgene Inc.INDUSTRY | 2 | Nov 20, 2018 | clinicaltrials |
| NCT03742388 | A Genomic Analysis of Evolution of Epithelia Ovarian Tumors | unknown | — | 40 | Lei LiOTHER | 1 | Nov 15, 2018 | clinicaltrials |
| NCT03742856 | A Multi-omics Study of Epithelial Ovarian Cancer | unknown | — | 80 | Lei LiOTHER | 1 | Nov 15, 2018 | clinicaltrials |
| NCT03291262 | Survival Outcomes of Ovarian Malignancies in Chinese Population | unknown | — | 5,000 | Lei LiOTHER | 1 | Nov 14, 2018 | clinicaltrials |
| NCT03388996 | Pelvic Microbiomes of Benign and Malignant Ovarian Diseases(MTBOD-1) | unknown | — | 40 | Lei LiOTHER | 1 | Nov 14, 2018 | clinicaltrials |
| NCT03738319 | Non-coding RNA in the Exosome of the Epithelia Ovarian Cancer | unknown | — | 160 | Lei LiOTHER | 1 | Nov 14, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Feb 28, 2020source: clinicaltrials